Nancy A Simonian
CIK 1359574 · President & CEO · last filed 2026-03-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
5
Total Filings
52
Lifetime Open-Market Net
-$2.15M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GENB | Director | — | $12.96 | — | $0 | 1 | 2026-03-02 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | Director | 12,000 | $0.00 | $5 | -$45.8K | 22 | 2024-12-04 |
| Seagen Inc. (SGEN) Delisted | Director | 0 | $228.74 | $0 | $0 | 14 | 2023-12-15 |
| Evelo Biosciences, Inc. (EVLO) Delisted | Director | — | $0.00 | — | $0 | 3 | 2020-06-18 |
| MILLENNIUM PHARMACEUTICALS INC (MLNM) Delisted | Chief Medical Officer | 4,975 | — | — | -$2.10M | 6 | 2008-05-15 |
Recent Filings · Page 2 of 6
52 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-11-02 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Mixed | +26,724 | -$29.8K | EDGAR |
| 2023-06-02 | Seagen Inc. (SGEN) Delisted | Grant (A) | +2,044 | $0 | EDGAR |
| 2023-04-04 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Mixed | +4,148 | -$4.8K | EDGAR |
| 2023-02-21 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-12-14 | Seagen Inc. (SGEN) Delisted | Exer (M) | +8,750 | $321.1K | EDGAR |
| 2022-10-11 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-17 | Seagen Inc. (SGEN) Delisted | Grant (A) | +1,503 | $0 | EDGAR |
| 2022-04-04 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Tax (F) | −58,883 | -$65.9K | EDGAR |
| 2022-03-04 | Seagen Inc. (SGEN) Delisted | Exer (M) | +25,000 | $501.0K | EDGAR |
| 2022-02-17 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.